SBC Medical Group Holdings, Inc.

Investment in OrangeTwist

January 2026

Disclaimer

This presentation contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's strategic investment and alliance with OrangeTwist, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," "targets" or "hopes" or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this presentation and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading "Risk Factors" and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), which are accessible on the SEC's website at www.sec.gov.

Investment in OrangeTwist

- Completion of a strategic minority investment in OrangeTwist, a leading U.S. medical spa platform
- Establishment of a structured collaboration framework with OrangeTwist and its longstanding institutional shareholders, Hildred Capital and Athyrium Capital

About OrangeTwist

- A leading national MedSpa platform that is well-positioned to capitalize on the high-value, growing aesthetic market in the U.S.
- Co-founded by world-renowned medical director Dr. Grant Stevens, M.D. F.A.C.S. and Clint Carnell
- Operations across 24 locations in CA, TX, WA, NV, CO, and NJ
- A curated portfolio of injectable, energy-based, and regenerative treatments

Founder and Investors

Clint Carnell (Co-Founder & Director)

- Co-Founder of OrangeTwist in 2015 and is a serial consumer healthcare entrepreneur with five successful exits
- Founder and Managing Partner of Greyspace
- Previously led Beauty Health's HydraFacial through its 2021 IPO and served as CEO of Myoscience, later acquired by Pacira

Hildred

- Invests as a healthcare-focused private equity firm in middle-market companies
- Partners with management teams to scale platforms and drive value creation

Athyrium Capital Management

- Founded in 2008 as a healthcare-dedicated asset manager
- Invests globally across healthcare with a multi-asset approach and flexible capital solutions

Business Development in the U.S.

- U.S. consumer trends are accelerating industry growth and expanding the medical aesthetics market
- The OrangeTwist investment includes a Future Collaboration Agreement that establishes a framework for pursuing commercial and strategic initiatives

U.S. Aesthetic Market Overview

Beyond the projected, steady growth to $71B in 2033, a massive untapped demographic offers significant additional upside



Source: Astute Analytica, *USA and Asia Pacific Aesthetic Medicine Market*, published June 2025

Future Collaboration Agreement

- **SBC's Expansion into the U.S.**
  Supporting SBC's U.S. entry through joint initiatives leveraging OrangeTwist's operating platform
- **OrangeTwist's Expansion into Asia**
  Co-planning MedSpa expansion in select Asian markets under a shared model
- **Sales of SBC's Products Through OrangeTwist**
  Positioning OrangeTwist to act as a non-exclusive U.S. retail/ distribution partner for select SBC products
- **Development of OrangeTwist-Branded or Co-Branded Products**
  Developing new clinic and e-commerce products jointly for the U.S., Japan, and Asia
- **Joint Venture Exploration**
  Exploring a potential JV, including the NEO Skin concept or similar collaborations

Global Expansion Strategy

- We aim to enhance global well-being, while pursuing the vision of becoming “the medical group chosen by the most customers in the world”
- Investment targets are selectively prioritized in areas aligned with our vision, strategic direction, and focus markets

Vision & Strategic Philosophy

- We strive to become the “the medical group chosen by the most customers in Japan” by 2035 and “the medical group chosen by the most customers in the world” by 2050, positioning global expansion at the core of our mid- to long-term strategy
- The global expansion thesis is guided by 3 core principles:

1. Partnering with high-performing regional operators
2. Deploying SBC’s differentiated operating expertise
3. Securing first-mover access to proprietary platforms and emerging longevity technologies

Market Focus

Health & Wellness

Regenerative, Aesthetic, Wellness Medicine

Human Optimization

Longevity, Medicine 4.0

Medical Tech & Platforms

AI-diagnostics, Telemedicine, Patient Experience Solutions

Global Expansion Strategy

- The disciplined, three phased approach—combined with the stability and profitability of the Japan business—positions us to deliver sustainable long-term growth, improved earnings quality, and increasing global brand value

Three-Phase Global Expansion Roadmap

Phase 1: Entry (2025-2026)

~30 Clinics

Create Optionality for Future Expansion

- Deepen market understanding
- Build strategic partnerships
- Deploy minority investments
- Launch new clinics

Phase 2: Scale (2027-2028)

50+ Clinics

Accelerate Growth and Strengthen Competitive Positioning

- Leverage accumulated market intelligence and SBC's proven operating model
- Pursue selective acquisitions and joint ventures

Phase 3: Leadership (2029-)

200+ Clinics

Establish SBC as a Leading Operator in the US and International Markets

- Diversify revenue streams
- Scale clinical platforms
- Drive technology-enabled operating leverage